{"organizations": [], "uuid": "375a5641f68e9e48d2a1a059794aebcc9836e937", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/29/globe-newswire-brainsway-reports-record-financial-results-for-first-quarter-of-2018-and-provides-corporate-update.html", "country": "US", "domain_rank": 767, "title": "Brainsway Reports Record Financial Results for First Quarter of 2018 and Provides Corporate Update", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.955, "site_type": "news", "published": "2018-05-29T15:00:00.000+03:00", "replies_count": 0, "uuid": "375a5641f68e9e48d2a1a059794aebcc9836e937"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/29/globe-newswire-brainsway-reports-record-financial-results-for-first-quarter-of-2018-and-provides-corporate-update.html", "ord_in_thread": 0, "title": "Brainsway Reports Record Financial Results for First Quarter of 2018 and Provides Corporate Update", "locations": [], "entities": {"persons": [{"name": "yaacov michlin", "sentiment": "none"}], "locations": [{"name": "n.j.", "sentiment": "none"}, {"name": "hackensack", "sentiment": "none"}, {"name": "brainsway", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "tase", "sentiment": "none"}, {"name": "brainsway ltd.", "sentiment": "none"}, {"name": "tms", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "First quarter revenues of $3.6 million represent a quarterly record and a 68% increase over first quarter 2017\nIncreased market demand and leasing model continue to generate sales growth\nHACKENSACK, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN), a leader in the advanced non-invasive treatment of brain disorders, today announced the Company’s financial results for the first quarter ended March 31, 2018, and provided a corporate update.\n“Our business model, based on leasing our Deep Transcranial Magnetic Stimulation system (Deep TMS), continues to generate significant market demand and meaningful revenue growth,” said Yaacov Michlin, Chief Executive Officer of Brainsway. “As evidence of this, we reported a quarterly record $3.6 million in total revenue in the first quarter of 2018, an increase of 68% over the first quarter of 2017. Moreover, we continued to increase backlog of committed projected revenues to approximately $25 million at the end of the first quarter.”\n“Early in the second quarter, we received 510(k) clearance from the FDA for our next-generation stimulator to be integrated with our Deep TMS system and we launched it with strong interest from the market during the APA conference. Moreover, we are awaiting the FDA’s response on our De Novo application to market our Deep TMS device for the treatment of obsessive compulsive disorder in the U.S. Brainsway’s current business continues to gain traction in the marketplace, while we are also focused on preparing the Company for its next stage of growth driven by clinical and technological innovation,” concluded Mr. Michlin.\nCorporate Highlights\nReceived U.S. Food and Drug Administration (FDA) clearance for next-generation stimulator, enhancing the complete Deep TMS system and streamlining treatment for physicians and their patients Continued development of a clinical trial protocol for the Deep TMS device to assess its safety and efficacy in the treatment of patients with opioid use disorder Anticipate regulatory decision shortly from FDA for the use of the Deep TMS system for the treatment of obsessive compulsive disorder Continued patient recruitment into multi-center smoking cessation and PTSD clinical trials for Deep TMS; completion of smoking cessation study expected by end of 2018\nFirst Quarter 2018 Financial Highlights\nLeasing model continues to generate significant quarter-over-quarter revenue growth Total first quarter 2018 revenue was a record $3.6 million, up 68% over the $2.1 million of total revenues in the first quarter of 2017\n-- Leasing revenues of $2.1 million in the first quarter of 2018\n-- Sales revenues of $1.5 million in the first quarter of 2018 Newly signed contracts increased Brainsway’s backlog at March 31, 2018, to $24.9 million in total committed projected revenues from current leasing customers, not including additional potential usage fees\nBalance Sheet\nAt March 31, 2018, the Company had cash, cash equivalents and short-term deposits of $15.4 million, as compared to cash, cash equivalents and short-term deposits of $16.5 million as of December 31, 2017. Brainsway’s cash use rate is approximately $1 million per quarter, with a reduction of cash burn rate to approximately $600,000 for operational expenses.\nAbout Brainsway\nBrainsway is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique and breakthrough technology called Deep TMS, which can reach the depth of the brain and produce nerve stimulation or suppression. In the US, the Company’s device is FDA cleared for the treatment of major depression (MDD), and about 90% of MDD patients are eligible for coverage (including from both private and governmental payors). The Company's systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders.\nForward Looking Statements\nThis press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our device studies; our products may not be approved by regulatory agencies: we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company those contemplated in such forward-looking statements.\nAny forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in Brainsway Ltd.'s periodic filings with the Tel-Aviv Stock Exchange.\nInvestor Contacts:\nHadar Levy\nChief Financial Officer\nhadarl@brainsway.com\nBob Yedid\nLifeSci Advisors\nbob@lifesciadvisors.com\n646-597-6989\nSource:Brainsway Ltd.", "external_links": ["https://www.globenewswire.com/Tracker?data=zrIXCZ8jeNZ9hQYhK1-uiQMQMVzkB9A351v6kzNYqoMHtgsTwC-pyYBYErh0bH56DQ8YNpae7nPgB1yQj2YlJEw_UicrDUclhTtSnJR60yg=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/fdcc24ba-b80c-4f9e-b598-6a7978c8f1db", "https://www.globenewswire.com/Tracker?data=bry4FWO_bm51rM74mUcN7tRCo_suRGSb7sGPKpAramG56I221x54C-njIwn01E9L5-R396c5VJYFx_sYEkgAKhjMpcclcD7h_rPxlLxlWfA="], "published": "2018-05-29T15:00:00.000+03:00", "crawled": "2018-05-29T17:17:36.000+03:00", "highlightTitle": ""}